blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4083627

EP4083627 - PROGNOSTIC BIOMARKER OF CANCER [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  30.09.2022
Database last updated on 31.08.2024
FormerThe international publication has been made
Status updated on  07.07.2021
Most recent event   Tooltip06.07.2024Amendment by applicant 
Applicant(s)For all designated states
Hoshi General Hospital, a Public Interest Incorporated Foundation
159-1, Mukaigawara-machi
Koriyama-shi, Fukushima 963-8501 / JP
For all designated states
Homma, Miwako
c/o Fukushima Medical University
1, Hikarigaoka
Fukushima-shi, Fukushima 960-1295 / JP
For all designated states
Homma, Yoshimi
c/o Fukushima Medical University
1, Hikarigaoka
Fukushima-shi, Fukushima 960-1295 / JP
For all designated states
Hashimoto, Yuko
c/o Fukushima Medical University
1, Hikarigaoka
Fukushima-shi, Fukushima 960-1295 / JP
[2022/44]
Inventor(s)01 / NOMIZU Tadashi
c/o Hoshi General Hospital, a public interest
incorporated foundation, 159-1, Mukaigawara-machi
Koriyama-shi, Fukushima 963-8501 / JP
02 / KIKO Yuichiro
c/o Fukushima Medical University, 1, Hikarigaoka
Fukushima-shi, Fukushima 960-1295 / JP
03 / HOMMA Miwako
c/o Fukushima Medical University, 1, Hikarigaoka
Fukushima-shi, Fukushima 960-1295 / JP
04 / HOMMA Yoshimi
c/o Fukushima Medical University, 1, Hikarigaoka
Fukushima-shi, Fukushima 960-1295 / JP
05 / HASHIMOTO Yuko
c/o Fukushima Medical University, 1, Hikarigaoka
Fukushima-shi, Fukushima 960-1295 / JP
 [2022/44]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2022/44]
Application number, filing date20904709.125.12.2020
[2022/44]
WO2020JP48650
Priority number, dateJP2019023409925.12.2019         Original published format: JP 2019234099
[2022/44]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021132544
Date:01.07.2021
Language:JA
[2021/26]
Type: A1 Application with search report 
No.:EP4083627
Date:02.11.2022
Language:EN
[2022/44]
Search report(s)International search report - published on:JP01.07.2021
(Supplementary) European search report - dispatched on:EP14.12.2023
ClassificationIPC:G01N33/574, C07K14/47, C12Q1/02, C12N9/12
[2024/03]
CPC:
G01N33/57415 (EP,US); C12N9/12 (EP,US); C12Y207/11001 (EP,US);
G01N33/57496 (EP); G01N33/68 (US); G01N2333/9121 (EP,US);
G01N2800/52 (EP); G01N2800/7028 (US) (-)
Former IPC [2022/44]G01N33/574, C07K14/47, C12Q1/02
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/44]
TitleGerman:PROGNOSTISCHER BIOMARKER VON KREBS[2022/44]
English:PROGNOSTIC BIOMARKER OF CANCER[2022/44]
French:BIOMARQUEUR DE PRONOSTIC DU CANCER[2022/44]
Entry into regional phase05.07.2022Translation filed 
05.07.2022National basic fee paid 
05.07.2022Search fee paid 
05.07.2022Designation fee(s) paid 
05.07.2022Examination fee paid 
Examination procedure05.07.2022Examination requested  [2022/44]
05.07.2024Amendment by applicant (claims and/or description)
05.07.2024Date on which the examining division has become responsible
Fees paidRenewal fee
05.07.2022Renewal fee patent year 03
20.12.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XYI]EP2472263  (COMMISSARIAT ENERGIE ATOMIQUE [FR]) [X] 11 * paragraph [0033]; claims 1,11-15 * [Y] 1-11 [I] 1-10;
 [A]  - LARAMAS ET AL, "Nuclear localization of protein kinase CK2 catalytic subunit (CK2@a) is associated with poor prognostic factors in human prostate cancer", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM NL, (20070316), vol. 43, no. 5, doi:10.1016/J.EJCA.2006.11.021, ISSN 0959-8049, pages 928 - 934, XP005919065 [A] 1-10 * abstract *

DOI:   http://dx.doi.org/10.1016/j.ejca.2006.11.021
 [A]  - FAUST R A ET AL, "Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, ELSEVIER, AMSTERDAM, NL, (19990901), vol. 31, no. 9, doi:10.1016/S1357-2725(99)00050-3, ISSN 1357-2725, pages 941 - 949, XP002437111 [A] 1-10 * abstract *

DOI:   http://dx.doi.org/10.1016/S1357-2725(99)00050-3
 [Y]  - BESTGEN BENOÎT ET AL, "2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action", JOURNAL OF MEDICINAL CHEMISTRY, US, (20190228), vol. 62, no. 4, doi:10.1021/acs.jmedchem.8b01765, ISSN 0022-2623, pages 1817 - 1836, XP055793780 [Y] 1-11 * abstract * * page 1827, column 2, paragraph 2 *

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.8b01765
 [Y]  - PFAFF M ET AL, "Casein kinase II accumulation in the nucleolus and its role in nucleolar phosphorylation", BIOCHIMICA ET BIOPHYSICA ACTA, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 969, no. 1, doi:10.1016/0167-4889(88)90093-6, ISSN 0167-4889, (19880402), pages 100 - 109, (19880402), XP025464516 [Y] 1-11 * abstract *

DOI:   http://dx.doi.org/10.1016/0167-4889(88)90093-6
International search[A]WO2005113835  (UNIV NORTHEASTERN [US], et al) [A] 1-11;
 [A]WO2008083998  (INST NAT SANTE RECH MED [FR], et al) [A] 1-11;
 [A]EP2472263  (COMMISSARIAT ENERGIE ATOMIQUE [FR]) [A] 1-11;
 [A]US2013230852  (YOU LIANG [US], et al) [A] 1-11;
 [PX]  - KATO HOMMA MIWAKO et al., "Intracellular localization of CK2a as a prognostic factor in invasive breast carcinomas", Cancer Science, (20201108), vol. 112, no. 2, pages 619 - 628, XP055839400 [PX] 1-11 * Abstract *

DOI:   http://dx.doi.org/10.1111/cas.14728
by applicant   - ROSS J.S. et al., Oncologist, (20030000), vol. 8, no. 4, pages 307 - 25
    - ALTSCHUL et al., Nuc. Acids. Res., (19770000), vol. 25, pages 3389 - 3402
    - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410
    - "TNM Classification of Malignant Tumours", UICC INTERNATIONAL CODEL.H. SOBINM.K. GOSPODAROWICZCH. WITTEKIND, TNM Classification of Malignant Tumours, Union for International Cancer Control
 JP20190234099
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.